CLOs on the Move

Neurocrine

www.neurocrine.com

 
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company`s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson`s disease, endometriosis* and uterine fibroids* , as well as clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Sherry Schnell
Chief Compliance Officer and Associate General Counsel Profile
Malcolm Lloyd-Smith
Chief Regulatory Officer Profile
Ingrid Delaet
Chief Regulatory Officer Profile
David Bradfute
Vice President and Head, Intellectual Property Profile
Darin Lippoldt
Chief Legal Officer Profile

Similar Companies

Logical Therapeutics

Logical Therapeutics is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Better Therapeutics

Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better expects to go public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the summer of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies.

NephroGenex

NephroGenex is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cardea

Cardeas BPU™ (Biosignal Processing Unit) is a biocompatible semiconductor capable of translating real-time streams of multiomics signals to digital information

DYNAMIS THERAPEUTICS

DYNAMIS THERAPEUTICS is a Jenkintown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.